Dr. Parker Catherine, MD

Claim this profile

The University of Alabama at Birmingham

Studies Neuroinflammatory Disease
Studies Breast Cancer
1 reported clinical trial
2 drugs studied

Area of expertise

1Neuroinflammatory Disease
Parker Catherine, MD has run 1 trial for Neuroinflammatory Disease. Some of their research focus areas include:
Stage II
Stage III
2Breast Cancer
Parker Catherine, MD has run 1 trial for Breast Cancer. Some of their research focus areas include:
Stage II
Stage III

Affiliated Hospitals

Image of trial facility.
The University Of Alabama At Birmingham

Clinical Trials Parker Catherine, MD is currently running

Image of trial facility.

PET Scans

for Brain Inflammation in Breast Cancer

This clinical study will use the small molecule translocator protein (TSPO) ligand, 18F-labeled DPA-714, to visualize and quantify neuroinflammation in treatment naive women with stage II-III newly diagnosed breast cancer (without brain metastases) prior to starting neoadjuvant chemotherapy treatment (baseline) and within 4 weeks after finishing neoadjuvant chemotherapy (NACT) with at least 2 cycles administered and before surgery. . The TSPO PET and MRI data acquired through this study will be correlated with cognitive test data, clinical data, and genetic testing collected in this study. We will enroll 20 participants in this study (20 participants with breast cancer). Study Aim 1: To examine the association between neuroinflammation and cancer related cognitive impairment (CRCI) in women with breast cancer before and after undergoing chemotherapy treatment. (Hypothesis 1): Treatment-naïve women with Stage II-III breast cancer (without known brain metastases) will experience increased amount of neuroinflammation and greater cognitive decline after completing neodjuvant Chemotherapy Treatment (NACT). (Hypothesis 2): Greater levels of neuroinflammation as measured by the amount and distribution of \[18F\]DPA-714 in the brain using PET/MRI after completing NACT will be associated with lower levels of cognitive functioning as measured by self-report and/or objective cognitive impairment/change. Neuroinflammation will be measured using PET with tracer \[18F\]DPA-714 using a simultaneous PET/MRI system, and cognitive functioning will be measured with self-report and objective neuropsychological measures. Exploratory Aim 2: To investigate the relationships between CRCI and quality of life (QOL) and everyday functioning in breast cancer survivors after completing chemotherapy treatment. For this Aim, we will assess QOL using self-report measures.
Recruiting1 award Phase 1

More about Parker Catherine, MD

Clinical Trial Related1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Parker Catherine, MD has experience with
  • [11C]PiB
  • 18F-labeled DPA-714
Breakdown of trials Parker Catherine, MD has run
Neuroinflammatory Disease
Breast Cancer
Cognitive Impairment

Other Doctors you might be interested in

Falkson Carla, MDThe University of Alabama at Birmingham
Gagandeep Choudhary, MDThe University of Alabama at Birmingham
Michele Kong, MDThe University of Alabama at Birmingham

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Parker Catherine, MD specialize in?
Parker Catherine, MD focuses on Neuroinflammatory Disease and Breast Cancer. In particular, much of their work with Neuroinflammatory Disease has involved Stage II patients, or patients who are Stage III.
Is Parker Catherine, MD currently recruiting for clinical trials?
Yes, Parker Catherine, MD is currently recruiting for 1 clinical trial in Birmingham Alabama. If you're interested in participating, you should apply.
Are there any treatments that Parker Catherine, MD has studied deeply?
Yes, Parker Catherine, MD has studied treatments such as [11C]PiB, 18F-labeled DPA-714.
What is the best way to schedule an appointment with Parker Catherine, MD?
Apply for one of the trials that Parker Catherine, MD is conducting.
What is the office address of Parker Catherine, MD?
The office of Parker Catherine, MD is located at: The University of Alabama at Birmingham, Birmingham, Alabama 35249 United States. This is the address for their practice at the The University of Alabama at Birmingham.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top